Загрузка...
Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell disease
BACKGROUND: The major therapeutic benefit of hydroxyurea, the only FDA-approved pharmacologic treatment for sickle cell disease (SCD), is directly related to fetal hemoglobin (HbF) production that leads to significant reduction of morbidity and mortality. However, potential adverse effects such as i...
Сохранить в:
| Опубликовано в: : | Clin Transl Med |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4824700/ https://ncbi.nlm.nih.gov/pubmed/27056246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40169-016-0092-7 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|